Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder

Table 1 Baseline demographic and clinical data of rheumatoid arthritis patients in different 12-month remission statuses

	Whole cohort (n = 273)	DAS28 remission (n = 102)	Only DAS28 remission (n = 75)	DAS28 + Boolean remission (n = 27)	Not in any remission (n = 171)
Age (years)	59.89 (7 to 85)	57.12 (7 to 85)	59.17 (26 to 85)	51.43 (7 to 75)	61.53 (30 to 86)
Disease duration (years)	13.43 (1 to 52)	11.1 (1 to 40)	12,23 (1 to 40)	7.91 (1 to 21)	14.68 (1 to 52)
Female (%)	74.7	68.6	66.7	74.1	78.4
RF positivity (%)	70.2	69.7	71.2	65.4	70.5
Anti-CCP positivity (%)	75.2	69.4	65.7	78.6	79.7
DAS28(4v)-CRP	5.33 ± 1.07	5.15 ± 1.1	5.18 ± 1.16	5.08 ± 0.9	5.44 ± 1.05
TJC28	10.24 ± 6.86	8.71 ± 6.83	9.19 ± 7.34	7.37 ± 5.05	11.15 ± 6.73
SJC28	9.86 ± 6.20	9.6 ± 6.25	9.73 ± 6.57	9.22 ± 5.36	10.02 ± 6.19
CRP (mg/dl)	2.76 ± 2.93	3.16 ± 3.14	3.23 ± 3.12	2.93 ± 3.26	2.53 ± 2.78
PGH	5.92 ± 2.28	5.6 ± 2.29	5.57 ± 2.33	5.68 ± 2.22	6.12 ± 2.26

Data presented as mean (range), mean ± standard deviation or percentage. DAS28, disease activity score based on 28-joint count; RF, rheumatoid factor; anti-CCP, anti-cyclic-citrullinated peptide antibody; DAS28(4v)-CRP, disease activity score based on 28-joint count, C-reactive protein and patient global health; TJC28, tender joint count out of 28 joints; SJC28, swollen joint count out of 28 joints; CRP, C-reactive protein; PGH, patient global health.